Tuberculosis (TB) is the world’s second leading infectious disease killer after COVID-19. Drug resistance to TB is a public health crisis. ISB researchers have developed algorithms to predict the efficacy of drugs in treating Mycobacterium tuberculosis (MTB), the causative agent for TB. These research findings were published in the journal Cell Reports Methods.
In the final ISB-Town Hall Seattle Science Series of 2021, ISB Assistant Professor Dr. Sean Gibbons sat down with UCSD Professor Dr. Jack Gilbert, and the two microbiome experts discussed past research, exciting science happening today, promising products and therapies on the horizon, and much more.
Congratulations to the Sui Huang Lab at ISB which has received a five-year $1.7 million R01 award from the National Institutes of Health and National Institute for General Medical Sciences to study cancer sub-population dynamics to understand and develop drugs to inhibit lethal cancer-drug resistance. The project proposal states that the work will: “develop a quantitative and formal framework for describing the temporal evolution of cell phenotype distribution in a…
